Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Raltegravir (RAL) received FDA approval in 2007 and is now used in treatment of both treatment-experienced and treatment-naïve patients.

Abstract & Commentary: Resistance to HIV Integrase Inhibitors